Raphael J Landovitz1, Ryan Kofron, Marybeth McCauley. 1. aUCLA Center for Clinical AIDS Research & Education, Los Angeles, California bFHI 360, Connecticut Avenue, Washington, District of Columbia, USA.
Abstract
PURPOSE OF REVIEW: Preexposure prophylaxis for HIV prevention is highly effective when taken as prescribed. Adherence to required dosing regimens for protection may pose challenges. Long-acting agents for HIV prevention may have the potential to improve adherence via favorable pharmacokinetics supportive of infrequent dosing. This review focuses on the potential benefits and considerations for the study and use of 2 long-acting injectable agents, cabotegravir (GSK1265744LA, CAB LA) and rilpivirine (TMC278LA, RPV LA), for use as chemoprophylaxis for HIV prevention. RECENT FINDINGS: Oral RPV is United States Food and Drug Administration approved for HIV treatment (in combination with other antiretrovirals). Both CAB LA and RPV LA are currently in phase 2a safety/tolerability/pharmacokinetic studies in anticipation and support of future efficacy evaluation. Both agents have favorable pharmacokinetics, and use is complicated by injection site reactions. SUMMARY: Long-acting injectable formulations, if safe and well tolerated, may improve pharmacokinetic coverage of exposures to HIV infection. Complexities around safety, tolerability, and starting/stopping protocols require careful consideration.
PURPOSE OF REVIEW: Preexposure prophylaxis for HIV prevention is highly effective when taken as prescribed. Adherence to required dosing regimens for protection may pose challenges. Long-acting agents for HIV prevention may have the potential to improve adherence via favorable pharmacokinetics supportive of infrequent dosing. This review focuses on the potential benefits and considerations for the study and use of 2 long-acting injectable agents, cabotegravir (GSK1265744LA, CAB LA) and rilpivirine (TMC278LA, RPV LA), for use as chemoprophylaxis for HIV prevention. RECENT FINDINGS: Oral RPV is United States Food and Drug Administration approved for HIV treatment (in combination with other antiretrovirals). Both CAB LA and RPV LA are currently in phase 2a safety/tolerability/pharmacokinetic studies in anticipation and support of future efficacy evaluation. Both agents have favorable pharmacokinetics, and use is complicated by injection site reactions. SUMMARY: Long-acting injectable formulations, if safe and well tolerated, may improve pharmacokinetic coverage of exposures to HIV infection. Complexities around safety, tolerability, and starting/stopping protocols require careful consideration.
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant Journal: Sci Transl Med Date: 2012-09-12 Impact factor: 17.956
Authors: Aimee Wilkin; Anton L Pozniak; Javier Morales-Ramirez; Sergio H Lupo; Mario Santoscoy; Beatriz Grinsztejn; Kiat Ruxrungtham; Laurence T Rimsky; Simon Vanveggel; Katia Boven Journal: AIDS Res Hum Retroviruses Date: 2011-10-17 Impact factor: 2.205
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: David A Margolis; Cynthia C Brinson; Graham H R Smith; Jerome de Vente; Debbie P Hagins; Joseph J Eron; Sandy K Griffith; Marty H St Clair; Marita C Stevens; Peter E Williams; Susan L Ford; Britt S Stancil; Melinda M Bomar; Krischan J Hudson; Kimberly Y Smith; William R Spreen Journal: Lancet Infect Dis Date: 2015-07-19 Impact factor: 25.071
Authors: Chasity D Andrews; William R Spreen; Hiroshi Mohri; Lee Moss; Susan Ford; Agegnehu Gettie; Kasi Russell-Lodrigue; Rudolf P Bohm; Cecilia Cheng-Mayer; Zhi Hong; Martin Markowitz; David D Ho Journal: Science Date: 2014-03-04 Impact factor: 47.728
Authors: Steven A John; H Jonathon Rendina; Tyrel J Starks; Christian Grov; Jeffrey T Parsons Journal: AIDS Patient Care STDS Date: 2019-01-17 Impact factor: 5.078
Authors: Corrine Ying Xuan Chua; Priya Jain; Andrea Ballerini; Giacomo Bruno; R Lyle Hood; Manas Gupte; Song Gao; Nicola Di Trani; Antonia Susnjar; Kathryn Shelton; Lane R Bushman; Marco Folci; Carly S Filgueira; Mark A Marzinke; Peter L Anderson; Ming Hu; Pramod Nehete; Roberto C Arduino; Jagannadha K Sastry; Alessandro Grattoni Journal: J Control Release Date: 2018-08-06 Impact factor: 9.776
Authors: Benedikt Pleuhs; Katherine G Quinn; Jennifer L Walsh; Andrew E Petroll; Steven A John Journal: AIDS Patient Care STDS Date: 2020-02-28 Impact factor: 5.078
Authors: Ethel D Weld; Md Sohel Rana; Ronald H Dallas; Andres F Camacho-Gonzalez; Patrick Ryscavage; Aditya H Gaur; Rana Chakraborty; Susan Swindells; Charles Flexner; Allison L Agwu Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Jillian Pintye; Kristin M Beima-Sofie; Pamela A Makabong'O; Anne Njoroge; Susan Brown Trinidad; Renee A Heffron; Jared M Baeten; Connie Celum; Daniel Matemo; John Kinuthia; Maureen C Kelley; Grace C John-Stewart Journal: AIDS Patient Care STDS Date: 2018-07-23 Impact factor: 5.078